This SCORE application submitted in response to the RFA from National Cancer Institute, will take advantage of the strengths in breast cancer research and treatment that exist at the Robert H. Lurie Comprehensive Cancer Center. The SPORE will provide the infrastructure to bring together basic scientists and clinicians to rapidly test new approaches in the prevention, early detection, diagnosis and treatment of human breast cancer. The specific themes of the SPORE are: 1. To investigate the role of diet and hormones in breast carcinogenesis. 2. To study the cell and molecular biology of breast cancer. 3. To evaluate factors associated with breast cancer risk and prevention. 4. To implement innovative translational therapies for breast cancer. The SPORE application consists of six principal research projects, three career development projects, five pilot projects and four Core facilities to support the research. The principal research projects are: #1. Drug resistance to anti-estrogens (PI Jordan), #2. Actions of estrogen agonists and antagonists by non-classical transcription pathways (PI Jameson), #3, Dietary and hormonal modifications of breast carcinogenesis in transgenic mice (PI Thor), #4. Estradiol levels in breast fluid, saliva and serum samples (PI Chatterton), #5. Anti-estrogens and breast density and pre-menopausal women (PI Morrow), #6 Angiostatic therapy for breast cancer: a translational study (PI Soff). The Core facilities include: Administration,, Tissue Resources, Clinical and Biostatistical Cores. The investigators selected to be part of the SPORE Program come from a variety of disciplines ranging from Clinical Programs to Chemical Engineering, Pathology and Microbiology-Immunology. To maintain meaningful communication between investigators, we will have monthly meetings of SPORE investigators, an annual retreat, monthly meetings of the Executive Committee and each investigator will be actively involved with at least one project (or core) in addition to their own. Based on the infrastructure described, our large patient population and our track record of productivity, we believe that the Robert H. Lurie Comprehensive Cancer Center is well suited for the SPORE program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA089018-03
Application #
6522785
Study Section
Special Emphasis Panel (ZCA1-GRB-V (O1))
Program Officer
Gomez, Jorge E
Project Start
2000-09-30
Project End
2005-08-31
Budget Start
2002-09-23
Budget End
2003-08-31
Support Year
3
Fiscal Year
2002
Total Cost
$2,735,690
Indirect Cost
Name
Northwestern University at Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Jordan, V Craig (2015) The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer 22:R1-31
Arora, Hans C; Jensen, Mark P; Yuan, Ye et al. (2012) Nanocarriers enhance Doxorubicin uptake in drug-resistant ovarian cancer cells. Cancer Res 72:769-78
Wu, Aiguo; Paunesku, Tatjana; Zhang, Zhuoli et al. (2011) A Multimodal Nanocomposite for Biomedical Imaging. AIP Conf Proc 1365:379
Thurn, Kenneth T; Arora, Hans; Paunesku, Tatjana et al. (2011) Endocytosis of titanium dioxide nanoparticles in prostate cancer PC-3M cells. Nanomedicine 7:123-30
Morrow, Monica; Chatterton Jr, Robert T; Rademaker, Alfred W et al. (2010) A prospective study of variability in mammographic density during the menstrual cycle. Breast Cancer Res Treat 121:565-74
Chatterton Jr, Robert Treat; Parker, Noah P; Habe-Evans, Mito et al. (2010) Breast ductal lavage for assessment of breast cancer biomarkers. Horm Cancer 1:197-204
Patel, Roshani R; Sengupta, Surojeet; Kim, Helen R et al. (2010) Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors. Eur J Cancer 46:1537-53
Balaburski, Gregor M; Dardes, Rita C; Johnson, Michael et al. (2010) Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance. Int J Oncol 37:387-98
Khan, Seema A; Lankes, Heather A; Patil, Deepa B et al. (2009) Ductal lavage is an inefficient method of biomarker measurement in high-risk women. Cancer Prev Res (Phila) 2:265-73
Jordan, V Craig; Lewis-Wambi, Joan S; Patel, Roshani R et al. (2009) New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis. Breast 18 Suppl 3:S10-7

Showing the most recent 10 out of 163 publications